Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent

Fig. 2

a HbA1c during the 12-week treatment with vidagliptin, sitagliptin, or linagliptin. There were no differences in HbA1c at baseline. Levels of HbA1c in the vildagliptin group were lower than in the linagliptin group at week 12 (P < 0.05). b HbA1c changes during the 12 weeks in the vildagliptin, sitagliptin, or linagliptin group. The change in HbA1c in the vildagliptin group was the greatest among the three groups (P < 0.05). c Proportion of patients. The proportion of patients achieving the target HbA1c levels in the vildagliptin group was the greatest among the three groups (P < 0.05)

Back to article page